Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

indivior plc - INDV

INDV

Close Chg Chg %
30.65 -0.18 -0.59%

Closed Market

30.47

-0.18 (0.59%)

Volume: 2.15M

Last Updated:

Apr 2, 2026, 4:00 PM EDT

Trade Now

Company Overview: indivior plc - INDV

INDV Key Data

Open

$29.99

 Day Range

29.65 - 30.57

52 Week Range

8.65 - 38.00

 Market Cap

$3.80B

Shares Outstanding

124.77M

 Public Float

120.66M

Beta

1.07

 Rev. Per Employee

N/A

P/E Ratio

18.57

 EPS

$1.68

Yield

0.00%

 Dividend

$0.10

EX-DIVIDEND DATE

Jun 16, 2016

 SHORT INTEREST

N/A

AVERAGE VOLUME

3.63M

  

INDV Performance

1 Week
 
 5.18%
 
1 Month
 
 -5.58%
 
3 Months
 
 -14.72%
 
1 Year
 
 233.01%
 
5 Years
 
 N/A
 

INDV Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 7
Full Ratings ➔

About indivior plc - INDV

Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company was founded on December 23, 2014 and is headquartered in North Chesterfield, VA.

INDV At a Glance

Indivior Pharmaceuticals, Inc.
10710 Midlothian Turnpike
North Chesterfield, Virginia 23235
Phone 1-804-379-1040 Revenue 1.24B
Industry Pharmaceuticals: Major Net Income 210.00M
Sector Health Technology 2025 Sales Growth 4.293%
Fiscal Year-end 12 / 2026 Employees 838
View SEC Filings

INDV Valuation

P/E Current 18.572
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 21.87
Price to Sales Ratio 3.707
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 12.563
Enterprise Value to Sales 3.833
Total Debt to Enterprise Value 0.074

INDV Efficiency

Revenue/Employee 1,478,520.286
Income Per Employee 250,596.659
Receivables Turnover 4.859
Total Asset Turnover 0.98

INDV Liquidity

Current Ratio 0.713
Quick Ratio 0.546
Cash Ratio 0.213

INDV Profitability

Gross Margin 82.002
Operating Margin 28.894
Pretax Margin 19.29
Net Margin 16.949
Return on Assets 16.607
Return on Equity N/A
Return on Total Capital 83.004
Return on Invested Capital 197.183

INDV Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital 138.735
Total Debt to Total Assets 29.153
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital 123.32
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Indivior Plc - INDV

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
901.00M 1.09B 1.19B 1.24B
Sales Growth
+13.91% +21.31% +8.69% +4.29%
Cost of Goods Sold (COGS) incl D&A
172.00M 201.00M 190.00M 223.00M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
21.00M 28.00M 29.00M 20.00M
Depreciation
14.00M 16.00M 12.00M 20.00M
Amortization of Intangibles
- 7.00M 12.00M 17.00M
COGS Growth
+22.86% +16.86% -5.47% +17.37%
Gross Income
729.00M 892.00M 998.00M 1.02B
Gross Income Growth
+11.98% +22.36% +11.88% +1.80%
Gross Profit Margin
+80.91% +81.61% +84.01% +82.00%
2022 2023 2024 2025 5-year trend
SG&A Expense
520.00M 634.00M 713.00M 658.00M
Research & Development
72.00M 106.00M 107.00M 80.00M
Other SG&A
448.00M 528.00M 606.00M 578.00M
SGA Growth
+12.07% +21.92% +12.46% -7.71%
Other Operating Expense
- - - -
-
Unusual Expense
297.00M 264.00M 249.00M 105.00M
EBIT after Unusual Expense
(88.00M) (6.00M) 36.00M 253.00M
Non Operating Income/Expense
22.00M 45.00M 19.00M 31.00M
Non-Operating Interest Income
19.00M 43.00M 23.00M 22.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
29.00M 38.00M 41.00M 45.00M
Interest Expense Growth
+11.54% +31.03% +7.89% +9.76%
Gross Interest Expense
29.00M 38.00M 41.00M 50.00M
Interest Capitalized
- - - 5.00M
-
Pretax Income
(95.00M) 1.00M 14.00M 239.00M
Pretax Income Growth
-150.00% +101.05% +1,300.00% +1,607.14%
Pretax Margin
-10.54% +0.09% +1.18% +19.29%
Income Tax
(42.00M) (1.00M) 11.00M 29.00M
Income Tax - Current - Domestic
64.00M 55.00M (6.00M) 76.00M
Income Tax - Current - Foreign
- - 11.00M (1.00M)
-
Income Tax - Deferred - Domestic
(106.00M) (56.00M) 25.00M 28.00M
Income Tax - Deferred - Foreign
- - (19.00M) (74.00M)
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(53.00M) 2.00M 2.00M 210.00M
Minority Interest Expense
- - - -
-
Net Income
(53.00M) 2.00M 2.00M 210.00M
Net Income Growth
-125.85% +103.77% -0.00% +10,400.00%
Net Margin Growth
-5.88% +0.18% +0.17% +16.95%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(53.00M) 2.00M 2.00M 210.00M
Preferred Dividends
- - - -
-
Net Income Available to Common
(53.00M) 2.00M 2.00M 210.00M
EPS (Basic)
-0.3813 0.0146 0.0151 1.68
EPS (Basic) Growth
-127.09% +103.83% +3.42% +11,025.83%
Basic Shares Outstanding
139.01M 137.31M 132.00M 125.00M
EPS (Diluted)
-0.3813 0.0141 0.015 1.6406
EPS (Diluted) Growth
-128.69% +103.70% +6.38% +10,837.33%
Diluted Shares Outstanding
139.01M 141.80M 133.00M 128.00M
EBITDA
230.00M 286.00M 314.00M 378.00M
EBITDA Growth
+10.05% +24.35% +9.79% +20.38%
EBITDA Margin
+25.53% +26.17% +26.43% +30.51%

Snapshot

Average Recommendation BUY Average Target Price 46.857
Number of Ratings 7 Current Quarters Estimate 0.746
FY Report Date 06 / 2026 Current Year's Estimate 3.121
Last Quarter’s Earnings 0.65 Median PE on CY Estimate N/A
Year Ago Earnings 2.50 Next Fiscal Year Estimate 3.441
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 5 5 7 7
Mean Estimate 0.75 0.82 3.12 3.44
High Estimates 0.83 0.94 3.34 3.76
Low Estimate 0.65 0.69 2.65 3.10
Coefficient of Variance 8.61 12.21 8.11 6.51

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 7 7 7
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Indivior Plc - INDV

Date Name Shares Transaction Value
Mar 6, 2026 Christian Heidbreder Chief Scientific Officer 246,509 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $31.98 per share 7,883,357.82
Mar 6, 2026 Woodrow Anderson Chief Accounting Officer 27,320 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2026 Woodrow Anderson Chief Accounting Officer 21,374 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $31.98 per share 683,540.52
Mar 6, 2026 Woodrow Anderson Chief Accounting Officer 29,657 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2026 Woodrow Anderson Chief Accounting Officer 24,638 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $31.98 per share 787,923.24
Mar 6, 2026 Ryan Preblick Chief Financial Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2026 Ryan Preblick Chief Financial Officer 317,292 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2026 Ryan Preblick Chief Financial Officer 230,343 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $31.98 per share 7,366,369.14
Mar 6, 2026 Woodrow Anderson Chief Accounting Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2026 Christian Heidbreder Chief Scientific Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2026 Christian Heidbreder Chief Scientific Officer 292,306 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2026 Jeffrey W. Burris Chief Legal Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2026 Jeffrey W. Burris Chief Legal Officer 71,518 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $31.98 per share 2,287,145.64
Mar 6, 2026 Jeffrey W. Burris Chief Legal Officer 107,550 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2026 Woodrow Anderson Chief Accounting Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 13, 2026 Patrick A. Barry Chief Commercial Officer 31,380 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 13, 2026 Joseph J. Ciaffoni Chief Executive Officer; Director 135,976 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 29, 2026 Stuart Anthony Kingsley Director 4,642 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 29, 2026 David E. Wheadon Director 20,350 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 29, 2026 Daniel A. Ninivaggi Director 20,645 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Indivior Plc in the News